Pharmacokinetics of Escalating Single-dose Administration of Cannabidiol to Cats

Overview

Journal J Vet Pharmacol Ther

Specialty Pharmacology

Date 2022 Oct 27

PMID 36300854

Authors

Aaron J Rozental

Daniel L Gustafson

Breonna R Kusick

Lisa R Bartner

Stephanie Cruz Castro

Stephanie McGrath

Affiliations

Soon will be listed here.

Abstract

This study aimed to assess the single-dose pharmacokinetics and tolerability of a cannabidiol (CBD) isolate in sunflower oil with escalating oral doses in eight healthy, purpose-bred cats. Eight cats were randomized into six dosing groups of four cats each. Cats were administered a single 2.5, 5, 10, 20, 40, or 80 mg/kg dose orally with at least a two-week washout in between doses. Behavior scoring, complete blood count, serum biochemistry analysis, physical examination, and CBD plasma levels were evaluated before and after dosing. All cats successfully completed the study. CBD was measured in the plasma of all cats dosed with CBD oil. The Cmax and AUC increased in a dose-proportional fashion across all dosing groups. There were no major bloodwork or behavioral changes although the BUN and creatinine values decreased after treatment across all doses. No adverse effects were observed, and behavioral changes were limited to head shaking, lip smacking, and hypersalivation immediately following dose administration. Single orally administered CBD doses up to 80 mg/kg were safe and well tolerated in this cohort of cats and display dose-proportional pharmacokinetics across a broad concentration.

Citing Articles

CBD for pets: navigating quality assurance, safety standards, and marketing strategies.

Rideout H, Cook A, Whetton A J Cannabis Res. 2025; 7(1):6.

PMID: 39849662 PMC: 11755934. DOI: 10.1186/s42238-024-00257-5.

Investigating the effect a single dose of cannabidiol has on measures of stress in cats when being transported in a carrier and meeting a novel person in an unfamiliar environment.

Weller J, Flint H, Hunt A, Ellerby Z, King T Front Vet Sci. 2024; 11:1476296.

PMID: 39559539 PMC: 11571322. DOI: 10.3389/fvets.2024.1476296.

Perioperative Analgesic and Sedative Effects of Cannabidiol in Cats Undergoing Ovariohysterectomy.

Zanelli G, Vieira G, Souza R, Aguiar A, Cassu R Animals (Basel). 2024; 14(16).

PMID: 39199820 PMC: 11350847. DOI: 10.3390/ani14162286.

Endocannabinoid system and phytocannabinoids in the main species of veterinary interest: a comparative review.

Di Salvo A, Chiaradia E, Sforna M, Rocca G Vet Res Commun. 2024; 48(5):2915-2941.

PMID: 39162768 PMC: 11442603. DOI: 10.1007/s11259-024-10509-7.

Pharmacokinetic of two oral doses of a 1:20 THC:CBD herbal extract in cats.

Lyons C, McEwan K, Munn-Patterson M, Vuong S, Alcorn J, Chicoine A Front Vet Sci. 2024; 11:1352495.

PMID: 38585296 PMC: 10996858. DOI: 10.3389/fvets.2024.1352495.

References

Verrico C, Wesson S, Konduri V, Hofferek C, Vazquez-Perez J, Blair E . A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain. 2020; 161(9):2191-2202. PMC: 7584779. DOI: 10.1097/j.pain.0000000000001896. View

Eichler M, Spinedi L, Unfer-Grauwiler S, Bodmer M, Surber C, Luedi M . Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med. 2012; 78(7):686-91. DOI: 10.1055/s-0031-1298334. View

Acierno M, Brown S, Coleman A, Jepson R, Papich M, Stepien R . ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2018; 32(6):1803-1822. PMC: 6271319. DOI: 10.1111/jvim.15331. View

Kulpa J, Paulionis L, Eglit G, Vaughn D . Safety and tolerability of escalating cannabinoid doses in healthy cats. J Feline Med Surg. 2021; 23(12):1162-1175. PMC: 8637357. DOI: 10.1177/1098612X211004215. View

Vaughn D, Kulpa J, Paulionis L . Preliminary Investigation of the Safety of Escalating Cannabinoid Doses in Healthy Dogs. Front Vet Sci. 2020; 7:51. PMC: 7029731. DOI: 10.3389/fvets.2020.00051. View

Gamble L, Boesch J, Frye C, Schwark W, Mann S, Wolfe L . Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. Front Vet Sci. 2018; 5:165. PMC: 6065210. DOI: 10.3389/fvets.2018.00165. View

Millar S, Stone N, Yates A, OSullivan S . A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol. 2018; 9:1365. PMC: 6275223. DOI: 10.3389/fphar.2018.01365. View

Birnbaum A, Karanam A, Marino S, Barkley C, Remmel R, Roslawski M . Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia. 2019; 60(8):1586-1592. DOI: 10.1111/epi.16093. View

Routledge P . Factors contributing to variability in drug pharmacokinetics. II. Drug distribution. J Clin Hosp Pharm. 1985; 10(1):15-23. DOI: 10.1111/j.1365-2710.1985.tb00713.x. View

10.

Chicoine A, Illing K, Vuong S, Pinto K, Alcorn J, Cosford K . Pharmacokinetic and Safety Evaluation of Various Oral Doses of a Novel 1:20 THC:CBD Herbal Extract in Dogs. Front Vet Sci. 2020; 7:583404. PMC: 7550466. DOI: 10.3389/fvets.2020.583404. View

11.

Rozental A, Gustafson D, Kusick B, Bartner L, Castro S, McGrath S . Pharmacokinetics of escalating single-dose administration of cannabidiol to cats. J Vet Pharmacol Ther. 2022; 46(1):25-33. PMC: 10092881. DOI: 10.1111/jvp.13100. View

12.

Brioschi F, Di Cesare F, Gioeni D, Rabbogliatti V, Ferrari F, DUrso E . Oral Transmucosal Cannabidiol Oil Formulation as Part of a Multimodal Analgesic Regimen: Effects on Pain Relief and Quality of Life Improvement in Dogs Affected by Spontaneous Osteoarthritis. Animals (Basel). 2020; 10(9). PMC: 7552307. DOI: 10.3390/ani10091505. View

13.

Corsetti S, Borruso S, Malandrucco L, Spallucci V, Maragliano L, Perino R . Cannabis sativa L. may reduce aggressive behaviour towards humans in shelter dogs. Sci Rep. 2021; 11(1):2773. PMC: 7854708. DOI: 10.1038/s41598-021-82439-2. View

14.

Fernandez-Trapero M, Perez-Diaz C, Espejo-Porras F, de Lago E, Fernandez-Ruiz J . Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders. Biomolecules. 2020; 10(2). PMC: 7072526. DOI: 10.3390/biom10020279. View

15.

McGrath S, Bartner L, Rao S, Packer R, Gustafson D . Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc. 2019; 254(11):1301-1308. DOI: 10.2460/javma.254.11.1301. View

16.

Lebkowska-Wieruszewska B, Stefanelli F, Chericoni S, Owen H, Poapolathep A, Lisowski A . Pharmacokinetics of Bedrocan®, a cannabis oil extract, in fasting and fed dogs: An explorative study. Res Vet Sci. 2018; 123:26-28. DOI: 10.1016/j.rvsc.2018.12.003. View

17.

Payne J, Brodbelt D, Luis Fuentes V . Blood Pressure Measurements in 780 Apparently Healthy Cats. J Vet Intern Med. 2016; 31(1):15-21. PMC: 5259628. DOI: 10.1111/jvim.14625. View

18.

Deabold K, Schwark W, Wolf L, Wakshlag J . Single-Dose Pharmacokinetics and Preliminary Safety Assessment with Use of CBD-Rich Hemp Nutraceutical in Healthy Dogs and Cats. Animals (Basel). 2019; 9(10). PMC: 6826847. DOI: 10.3390/ani9100832. View

19.

Bartner L, McGrath S, Rao S, Hyatt L, Wittenburg L . Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Can J Vet Res. 2018; 82(3):178-183. PMC: 6038832. View

20.

Zgair A, Wong J, Lee J, Mistry J, Sivak O, Wasan K . Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am J Transl Res. 2016; 8(8):3448-59. PMC: 5009397. View